

Australia's EpiAxis Therapeutics partners with University Health Newtork to study prostate cancer

20 September 2022 | News

Entered a collaboration to study a new epigenetics approach to prostate cancer treatment



Australian firm EpiAxis Therapeutics, a leading epigenetics company with a focus on cancer treatment and prevention recurrence, and University Health Network (UHN)- Canada's largest and leading research hospital - have entered into a collaboration to study a new approach to prostate cancer treatment.

As part of the agreement, EpiAxis Therapeutics will supply its lead peptide candidates for assessment in UHN's prostate cancer models, with the aim of dramatically enhancing the ability to improve treatment and survival of men with lethal prostate cancer (CaP).

EpiAxis Therapeutics CEO, Dr Jeremy Chrisp, said that while next generation genomic technologies have deepened the understanding of prostate cancer development and evolution, they have arguably reached a therapeutic plateau.

Dr Hansen He, Senior Scientist at UHN's Princess Margaret Cancer Centre, will be leading the project utilising EpiAxis' lead peptide candidates.

Dr He's research programme focuses on understanding epigenetic mechanisms underlying cancer development, progression and therapy response, with the aim of identifying epigenetic biomarkers and therapeutic targets to improve treatment outcomes for cancer patients.